DCTH

Delcath Systems Stock Price

12.65
0.07 (0.56%)
Upgrade to Real-Time
Afterhours (Closed)
12.65
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Delcath Systems Inc DCTH NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
0.07 0.56% 12.65 12.31 12.74 12.60 12.58 18:00:58
Bid Price Ask Price Spread Spread % News
12.10 13.00 0.90 6.92% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
408 28,375 $ 12.62 $ 358,066 70,111 6.06 - 12.90
Last Trade Time Type Quantity Stock Price Currency
16:00:00 185 $ 12.65 USD

Delcath Systems Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 49.26M 3.89M 3.87M $ 1.58M $ - -450.31 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 72.26k 72.10%

more financials information »

Delcath Systems News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical DCTH Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week11.7712.8511.7512.5833,0380.887.48%
1 Month9.0612.908.6011.5662,0613.5939.62%
3 Months7.6812.907.159.6665,3954.9764.71%
6 Months3.7712.906.069.2869,7008.88235.54%
1 Year3.7712.906.069.2869,7008.88235.54%
3 Years0.084912.900.080.153518719,272,93312.5714,799.88%
5 Years8.1612.900.0150.177753714,686,7104.4955.02%

Delcath Systems Description

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.